Development of an in vitro screening assay to test the antiinflammatory properties of dietary supplements and pharmacologic agents

Uma Singh, James Tabibian, Senthil K. Venugopal, Sridevi Devaraj, Ishwarlal Jialal

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Background: Monocytes and macrophages are critical in atherosclerosis and on stimulation secrete proinflammatory, proatherogenic cytokines such as tumor necrosis factor (TNF)-α and interleukin (IL)-1β, which have been shown to be present in atherosclerotic lesions. The aim of this study was to develop a rapid in vitro screening assay to test the antiinflammatory effects of different compounds. Methods and Results: THP-1 cells (human monocytic cell line) were stimulated with different concentrations of lipopolysaccharide (LPS; 0 to 1000 μg/L) and for different times (4, 12, and 24 h), and the secretion of proinflammatory cytokines (IL-1, IL-6, and TNF-α) was assessed. TNF-α secretion was maximum at the lowest LPS concentration (100 μg/L) and at shortest duration of incubation (4 h). Maximum secretion of IL-1β and IL-6 was achieved at 24 h with higher doses of LPS. Treatment of THP-1 with various test compounds such as dietary supplements (α-tocopherol, N-acetylcysteine, catechin and epigallocatechin gallate) as well as pharmacologic agents (statins, peroxisome proliferator-activated receptor-γ agonists, and an angiotensin II receptor blocker) significantly inhibited LPS-stimulated TNF-α release. Conclusions: The release of TNF-α after stimulation of THP-1 cells with LPS is a valid model system to test novel compounds for potential antiinflammatory effects.

Original languageEnglish (US)
Pages (from-to)2252-2256
Number of pages5
JournalClinical Chemistry
Volume51
Issue number12
DOIs
StatePublished - Dec 2005

Fingerprint

Dietary supplements
Dietary Supplements
Assays
Screening
Anti-Inflammatory Agents
Tumor Necrosis Factor-alpha
Interleukin-1
Interleukin-6
Cytokines
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Peroxisome Proliferator-Activated Receptors
Tocopherols
Macrophages
Angiotensin Receptor Antagonists
Acetylcysteine
Lipopolysaccharides
Monocytes
Atherosclerosis
Cells
In Vitro Techniques

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Development of an in vitro screening assay to test the antiinflammatory properties of dietary supplements and pharmacologic agents. / Singh, Uma; Tabibian, James; Venugopal, Senthil K.; Devaraj, Sridevi; Jialal, Ishwarlal.

In: Clinical Chemistry, Vol. 51, No. 12, 12.2005, p. 2252-2256.

Research output: Contribution to journalArticle

Singh, Uma ; Tabibian, James ; Venugopal, Senthil K. ; Devaraj, Sridevi ; Jialal, Ishwarlal. / Development of an in vitro screening assay to test the antiinflammatory properties of dietary supplements and pharmacologic agents. In: Clinical Chemistry. 2005 ; Vol. 51, No. 12. pp. 2252-2256.
@article{07c7dc8ff33643d19973db1b7e16d2eb,
title = "Development of an in vitro screening assay to test the antiinflammatory properties of dietary supplements and pharmacologic agents",
abstract = "Background: Monocytes and macrophages are critical in atherosclerosis and on stimulation secrete proinflammatory, proatherogenic cytokines such as tumor necrosis factor (TNF)-α and interleukin (IL)-1β, which have been shown to be present in atherosclerotic lesions. The aim of this study was to develop a rapid in vitro screening assay to test the antiinflammatory effects of different compounds. Methods and Results: THP-1 cells (human monocytic cell line) were stimulated with different concentrations of lipopolysaccharide (LPS; 0 to 1000 μg/L) and for different times (4, 12, and 24 h), and the secretion of proinflammatory cytokines (IL-1, IL-6, and TNF-α) was assessed. TNF-α secretion was maximum at the lowest LPS concentration (100 μg/L) and at shortest duration of incubation (4 h). Maximum secretion of IL-1β and IL-6 was achieved at 24 h with higher doses of LPS. Treatment of THP-1 with various test compounds such as dietary supplements (α-tocopherol, N-acetylcysteine, catechin and epigallocatechin gallate) as well as pharmacologic agents (statins, peroxisome proliferator-activated receptor-γ agonists, and an angiotensin II receptor blocker) significantly inhibited LPS-stimulated TNF-α release. Conclusions: The release of TNF-α after stimulation of THP-1 cells with LPS is a valid model system to test novel compounds for potential antiinflammatory effects.",
author = "Uma Singh and James Tabibian and Venugopal, {Senthil K.} and Sridevi Devaraj and Ishwarlal Jialal",
year = "2005",
month = "12",
doi = "10.1373/clinchem.2005.056093",
language = "English (US)",
volume = "51",
pages = "2252--2256",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "12",

}

TY - JOUR

T1 - Development of an in vitro screening assay to test the antiinflammatory properties of dietary supplements and pharmacologic agents

AU - Singh, Uma

AU - Tabibian, James

AU - Venugopal, Senthil K.

AU - Devaraj, Sridevi

AU - Jialal, Ishwarlal

PY - 2005/12

Y1 - 2005/12

N2 - Background: Monocytes and macrophages are critical in atherosclerosis and on stimulation secrete proinflammatory, proatherogenic cytokines such as tumor necrosis factor (TNF)-α and interleukin (IL)-1β, which have been shown to be present in atherosclerotic lesions. The aim of this study was to develop a rapid in vitro screening assay to test the antiinflammatory effects of different compounds. Methods and Results: THP-1 cells (human monocytic cell line) were stimulated with different concentrations of lipopolysaccharide (LPS; 0 to 1000 μg/L) and for different times (4, 12, and 24 h), and the secretion of proinflammatory cytokines (IL-1, IL-6, and TNF-α) was assessed. TNF-α secretion was maximum at the lowest LPS concentration (100 μg/L) and at shortest duration of incubation (4 h). Maximum secretion of IL-1β and IL-6 was achieved at 24 h with higher doses of LPS. Treatment of THP-1 with various test compounds such as dietary supplements (α-tocopherol, N-acetylcysteine, catechin and epigallocatechin gallate) as well as pharmacologic agents (statins, peroxisome proliferator-activated receptor-γ agonists, and an angiotensin II receptor blocker) significantly inhibited LPS-stimulated TNF-α release. Conclusions: The release of TNF-α after stimulation of THP-1 cells with LPS is a valid model system to test novel compounds for potential antiinflammatory effects.

AB - Background: Monocytes and macrophages are critical in atherosclerosis and on stimulation secrete proinflammatory, proatherogenic cytokines such as tumor necrosis factor (TNF)-α and interleukin (IL)-1β, which have been shown to be present in atherosclerotic lesions. The aim of this study was to develop a rapid in vitro screening assay to test the antiinflammatory effects of different compounds. Methods and Results: THP-1 cells (human monocytic cell line) were stimulated with different concentrations of lipopolysaccharide (LPS; 0 to 1000 μg/L) and for different times (4, 12, and 24 h), and the secretion of proinflammatory cytokines (IL-1, IL-6, and TNF-α) was assessed. TNF-α secretion was maximum at the lowest LPS concentration (100 μg/L) and at shortest duration of incubation (4 h). Maximum secretion of IL-1β and IL-6 was achieved at 24 h with higher doses of LPS. Treatment of THP-1 with various test compounds such as dietary supplements (α-tocopherol, N-acetylcysteine, catechin and epigallocatechin gallate) as well as pharmacologic agents (statins, peroxisome proliferator-activated receptor-γ agonists, and an angiotensin II receptor blocker) significantly inhibited LPS-stimulated TNF-α release. Conclusions: The release of TNF-α after stimulation of THP-1 cells with LPS is a valid model system to test novel compounds for potential antiinflammatory effects.

UR - http://www.scopus.com/inward/record.url?scp=28044446082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28044446082&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2005.056093

DO - 10.1373/clinchem.2005.056093

M3 - Article

C2 - 16166164

AN - SCOPUS:28044446082

VL - 51

SP - 2252

EP - 2256

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 12

ER -